<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04722146</url>
  </required_header>
  <id_info>
    <org_study_id>CR108927</org_study_id>
    <secondary_id>2020-004404-33</secondary_id>
    <secondary_id>64007957MMY1004</secondary_id>
    <nct_id>NCT04722146</nct_id>
  </id_info>
  <brief_title>A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma</brief_title>
  <official_title>A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety and tolerability of teclistamab when&#xD;
      administered in different combination regimen and to identify the optimal dose(s) of&#xD;
      teclistamab combination regimens.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 11, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 2 year and 5 months</time_frame>
    <description>An AE can be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with AEs by Severity</measure>
    <time_frame>Up to 2 year and 5 months</time_frame>
    <description>Number of participants with AEs by severity will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Abnormalities in Laboratory Values</measure>
    <time_frame>Up to 2 year and 5 months</time_frame>
    <description>Number of participants with abnormalities in laboratory values (such as serum chemistry, hematology) will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Dose-Limiting Toxicity (DLT)</measure>
    <time_frame>Up to Cycle 2 Day 21 (each cycle is of 28 days for Treatment Regimen A and 21 days for Treatment Regimen B)</time_frame>
    <description>The Dose Limiting Toxicities (DLTs) are based on drug related adverse events and defined as any of the following events: hematological / non hematological toxicity of Grade 3 or higher.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 2 year and 5 months</time_frame>
    <description>ORR is defined as the proportion of participants who achieve partial response (PR) or better according to the international myeloma working group (IMWG) 2016 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Very Good Partial Response (VGPR) or Better Response Rate</measure>
    <time_frame>Up to 2 year and 5 months</time_frame>
    <description>VGPR or better response rate is defined as the proportion of participants who achieve a VGPR or better response (stringent complete response [sCR]+ complete response [CR]+VGPR) according to the IMWG 2016 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) or Better Response Rate</measure>
    <time_frame>Up to 2 year and 5 months</time_frame>
    <description>CR or better response rate is defined as the proportion of participants who achieve a CR or better response (sCR+CR) according to the IMWG 2016 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stringent Complete Response (sCR) Rate</measure>
    <time_frame>Up to 2 year and 5 months</time_frame>
    <description>sCR rate is defined as the proportion of participants who achieve an sCR according to the IMWG 2016 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 2 year and 5 months</time_frame>
    <description>Duration of response is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of progressive disease (PD), per IMWG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>Up to 2 year and 5 months</time_frame>
    <description>Time to response is defined as the time between date of first dose of study treatment and the first efficacy evaluation at which the participant has met all criteria for PR or better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Teclistamab</measure>
    <time_frame>Up to 2 year and 5 months</time_frame>
    <description>Serum concentrations of teclistamab will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Daratumumab</measure>
    <time_frame>Up to 2 year and 5 months</time_frame>
    <description>Serum concentrations of daratumumab will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Nirogacestat</measure>
    <time_frame>Up to 2 year and 5 months</time_frame>
    <description>Serum concentration of nirogacestat will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Presence of Anti-Drug Antibodies to Teclistamab</measure>
    <time_frame>Up to 2 year and 5 months</time_frame>
    <description>Number of participants with anti-drug antibodies to teclistamab will be reported for all treatment regimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Presence of Anti-Drug Antibodies to Daratumumab</measure>
    <time_frame>Up to 2 year and 5 months</time_frame>
    <description>Number of participants with anti-drug antibodies to daratumumab will be reported for Treatment Regimen A, B, and E.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Presence of Anti-Drug Antibodies to Recombinant Human Hyaluronidase PH20 Enzyme (rHuPH20)</measure>
    <time_frame>Up to 2 year and 5 months</time_frame>
    <description>Number of participants with anti-drug antibodies to rHuPH20 will be reported for Treatment Regimen A, B, and E.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment Regimen A: Teclistamab + Daratumumab + Pomalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive teclistamab plus daratumumab plus pomalidomide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Regimen B: Teclistamab + Daratumumab + Lenalidomide + Bortezomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive teclistamab plus daratumumab plus lenalidomide plus bortezomib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Regimen C: Teclistamab + Nirogacestat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive teclistamab plus nirogacestat.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Regimen D: Teclistamab + Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive teclistamab plus lenalidomide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Regimen E: Teclistamab + Daratumumab + Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive teclistamab plus daratumumab plus lenalidomide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teclistamab</intervention_name>
    <description>Participants will receive teclistamab.</description>
    <arm_group_label>Treatment Regimen A: Teclistamab + Daratumumab + Pomalidomide</arm_group_label>
    <arm_group_label>Treatment Regimen B: Teclistamab + Daratumumab + Lenalidomide + Bortezomib</arm_group_label>
    <arm_group_label>Treatment Regimen C: Teclistamab + Nirogacestat</arm_group_label>
    <arm_group_label>Treatment Regimen D: Teclistamab + Lenalidomide</arm_group_label>
    <arm_group_label>Treatment Regimen E: Teclistamab + Daratumumab + Lenalidomide</arm_group_label>
    <other_name>JNJ-64007957</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Participants will receive daratumumab.</description>
    <arm_group_label>Treatment Regimen A: Teclistamab + Daratumumab + Pomalidomide</arm_group_label>
    <arm_group_label>Treatment Regimen B: Teclistamab + Daratumumab + Lenalidomide + Bortezomib</arm_group_label>
    <arm_group_label>Treatment Regimen E: Teclistamab + Daratumumab + Lenalidomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Participants will receive pomalidomide.</description>
    <arm_group_label>Treatment Regimen A: Teclistamab + Daratumumab + Pomalidomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Participants will receive lenalidomide.</description>
    <arm_group_label>Treatment Regimen B: Teclistamab + Daratumumab + Lenalidomide + Bortezomib</arm_group_label>
    <arm_group_label>Treatment Regimen D: Teclistamab + Lenalidomide</arm_group_label>
    <arm_group_label>Treatment Regimen E: Teclistamab + Daratumumab + Lenalidomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Participants will receive bortezomib.</description>
    <arm_group_label>Treatment Regimen B: Teclistamab + Daratumumab + Lenalidomide + Bortezomib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nirogacestat</intervention_name>
    <description>Participants will receive nirogacestat.</description>
    <arm_group_label>Treatment Regimen C: Teclistamab + Nirogacestat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have documented initial diagnosis of multiple myeloma according to international&#xD;
             myeloma working group (IMWG) diagnostic criteria&#xD;
&#xD;
          -  Meet treatment regimen-specific requirements as follows: Treatment Regimen A&#xD;
             (teclistamab [tec]-daratumumab [dara]-pomalidomide [pom]) only: Participant has&#xD;
             relapsed or refractory multiple myeloma and has received 1 to 3 prior lines of&#xD;
             therapy, including exposure to a proteasome inhibitor (PI) and lenalidomide; Treatment&#xD;
             Regimen B (tec-dara-lenalidomide [len]-bortezomib [bor]) only: Participant has newly&#xD;
             diagnosed or relapsed/refractory multiple myeloma and is naive to treatment with&#xD;
             lenalidomide; Treatment Regimen C (tec-nirogacestat [niro]) only: Participant has&#xD;
             relapsed or refractory multiple myeloma and has 1) received 3 or more prior lines of&#xD;
             therapy or 2) is double refractory to a PI and an immunomodulatory drug (IMiD) and&#xD;
             triple exposed to a PI, an IMiD, and an anti-cluster of differentiation (CD)38&#xD;
             monoclonal antibody (mAb); Treatment Regimen D (tec-len) only: Participant has&#xD;
             multiple myeloma and has received greater than or equal to (&gt;=) 2 prior lines of&#xD;
             therapy, including exposure to a PI, an IMiD, and an anti-CD38 mAb; Treatment Regimen&#xD;
             E (tec-dara-len) only: Participant has multiple myeloma and has received 1 to 3 prior&#xD;
             lines of therapy, including exposure to a PI and an IMiD&#xD;
&#xD;
          -  Have measurable disease at screening as defined by at least one of the following:&#xD;
             serum M-protein level &gt;= 1.0 gram/deciliter (g/dL); or urine M-protein level &gt;= 200&#xD;
             milligrams (mg)/24 hours; or light chain multiple myeloma: serum immunoglobulin (Ig)&#xD;
             free light chain (FLC) &gt;= 10 milligram/deciliter (mg/dL) and abnormal serum Ig kappa&#xD;
             lambda FLC ratio&#xD;
&#xD;
          -  A woman of childbearing potential must have a negative serum (beta human chorionic&#xD;
             gonadotropin [hCG]) pregnancy test at screening and a negative urine or serum&#xD;
             pregnancy test within 24 hours before the start of study treatment administration and&#xD;
             must agree to further serum or urine pregnancy tests during the study&#xD;
&#xD;
          -  A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted&#xD;
             reproduction during the study and for at least 100 days after the last dose of study&#xD;
             treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with any therapy that targets B-cell maturation antigen (BCMA): This&#xD;
             exclusion does not apply to Treatment Regimen C&#xD;
&#xD;
          -  Live, attenuated vaccine within 30 days before the first dose of study treatment&#xD;
&#xD;
          -  Received a cumulative dose of corticosteroids equivalent to &gt;= 140 mg of prednisone&#xD;
             within the 14-day period before the start of study treatment administration&#xD;
&#xD;
          -  Active central nervous system (CNS) involvement or exhibition of clinical signs of&#xD;
             meningeal involvement of multiple myeloma. If either is suspected, brain magnetic&#xD;
             resonance imaging (MRI) and lumbar cytology are required&#xD;
&#xD;
          -  Known to be seropositive for human immunodeficiency virus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research and Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research and Development LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College Of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alfred Health</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle Hospital</name>
      <address>
        <city>Waratah</city>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZA</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Leon Bérard</name>
      <address>
        <city>Lyon Cedex 8</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chu Rennes - Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du cancer de Toulouse-Oncopole</name>
      <address>
        <city>TOULOUSE Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie Nhs Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Trust Sutton</name>
      <address>
        <city>Surrey</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108927</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

